Guillain-Barré Syndrome, or Acute on Chronic Inflammatory Demyelinating Polyneuropathy, Following Moderna Covid-19 Vaccine

Abo-Zed, Abdelrhman; Pinevich, Anthony

doi:10.1016/j.chest.2021.07.838

Cited by 9 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, one of the cases had a similar presentation years prior after the influenza vaccine, but he was asymptomatic since then. 259 All cases had a good recovery after standard treatment. In the UK cohort on GBS within 4 weeks after COVID-19 vaccines, four out of 16 patients were diagnosed with acute-onset CIDP.…”

Section: Covid-19 Vaccines Cidp and Other Neuropathiesmentioning

confidence: 87%

See 1 more Smart Citation

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Taga

Lauria

2022

J Peripheral Nervous Sys

View full text Add to dashboard Cite

Increasing literature has linked COVID‐19 to peripheral nervous system (PNS) diseases. In addition, as we move from the pandemic to the vaccination era, literature interest is shifting towards the potential association between COVID‐19 vaccines and PNS manifestations. We reviewed published literature on COVID‐19, COVID‐19 vaccines and PNS manifestations between 1 January 2020 and 1 December 2021. For Guillain‐Barré syndrome (GBS), isolated cranial neuropathy (ICN) and myositis associated with COVID‐19, the demographic, clinical, laboratory, electrophysiological and imaging features were included in a narrative synthesis. We identified 169 studies on COVID‐19‐associated complications, including 63 papers (92 patients) on GBS, 29 papers (37 patients) on ICN and 11 papers (18 patients) on myositis. Additional clinical phenotypes included chronic inflammatory demyelinating polyneuropathy, vasculitic neuropathies, neuralgic amyotrophy, critical care‐related complications, and myasthenia gravis. PNS complications secondary to COVID‐19 vaccines have been reported during randomized clinical trials, in real‐world case reports, and during large‐scale surveillance programs. These mainly include cases of GBS, Bell's palsy, and cases of neuralgic amyotrophy. Based on our extensive review of the literature, any conclusion about a pathophysiological correlation between COVID‐19 and PNS disorders remains premature, and solely supported by their temporal association, while epidemiological and pathological data are insufficient. The occurrence of PNS complications after COVID‐19 vaccines seems limited to a possible higher risk of facial nerve palsy and GBS, to a degree that widespread access to the ongoing vaccination campaign should not be discouraged, while awaiting for more definitive data from large‐scale surveillance studies.

show abstract

Section: Covid-19 Vaccines Cidp and Other Neuropathiesmentioning

confidence: 87%

“…In our review, we found isolated reports of "acute onset" CIDP following Moderna 259 and AstraZeneca vaccines, 235,260 in all cases 3 weeks after the first dose. Of note, one of the cases had a similar presentation years prior after the influenza vaccine, but he was asymptomatic since then.…”

Section: Covid-19 Vaccines Cidp and Other Neuropathiesmentioning

confidence: 99%

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Taga

Lauria

2022

J Peripheral Nervous Sys

View full text Add to dashboard Cite

show abstract

“…Demyelinating Polyneuropathy] with COVID-19 and COVID-19 vaccines. Abo-Zed and Pinevich reported a case of GBS that developed shortly after the Moderna COVID-19 vaccine which subsequently evolved into CIDP [8]. Of note, this patient had a history of GBS/AIDP four years ago after receiving the influenza vaccine.…”

Section: Concrete Data Exist On the Occurrence Of Aidp [Acute Inflamm...mentioning

confidence: 89%

Chronic Inflammatory Demyelinating Polyneuropathy Incidence in Covid-19 and Covid-19 Vaccines

Singh¹

2022

J Med Healthcare

View full text Add to dashboard Cite

Chronic Inflammatory Demyelinating Polyneuropathy [CIDP] is the most common autoimmune polyneuropathy in adults. CIDP is a demyelinating disease. It is an immune-mediated illness in which the precise mechanism behind the pathophysiology of the immune response is unknown. CIDP is an immune-mediated condition in which both T-cell and humoral mediated immune mechanisms act against myelin components. It is characterized by subacute to chronic onset [> 8 weeks], weakness [both proximal and distal], cyto-albuminologic dissociation [increased CSF protein without pleocytosis], and electrodiagnostic characteristics of asymmetric conduction velocity slowing with features of conduction block [1]. The presence of F-wave latency distinguishes CIDP from other demyelinating neuropathies [2,3]. Nerve pathology findings of CIDP are segmental demyelination, onion bulb formation, perineural inflammation, and axonal degeneration.

show abstract

“…There is convincing evidence regarding acute inflammatory demyelinating polyneuropathy (AIDP) following vaccination with COVID-19 and COVID-19 vaccines (including Moderna). Abo-Zed and Pinevich reported a case of GBS that developed shortly after the Moderna COVID-19 vaccine, which subsequently evolved into CIDP [ 25 ]. Of note, this patient had a history of GBS/AIDP four years ago after receiving the influenza vaccine.…”

Section: Discussionmentioning

confidence: 99%

Chronic Inflammatory Demyelinating Polyneuropathy Post-mRNA-1273 Vaccination

Singh¹,

Sanna²,

Adhikari³

et al. 2022

Cureus

View full text Add to dashboard Cite

Guillain-Barré Syndrome, or Acute on Chronic Inflammatory Demyelinating Polyneuropathy, Following Moderna Covid-19 Vaccine

Cited by 9 publications

References 0 publications

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era

Chronic Inflammatory Demyelinating Polyneuropathy Incidence in Covid-19 and Covid-19 Vaccines

Chronic Inflammatory Demyelinating Polyneuropathy Post-mRNA-1273 Vaccination

Contact Info

Product

Resources

About